TATDN2P3

Across TCGA pan-cancer cohorts, TATDN2P3 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TATDN2P3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TATDN2P3 RNA is repressed in tumor relative to normal tissue. In most cancer types TATDN2P3 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and STAD are the cancer types where TATDN2P3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TATDN2P3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	−0.025	.007	5	view →
KICH	Female	II,III,IV	−0.048	.003	4	view →
STAD	Male	All	−0.031	.005	3	view →
COAD	Male	All	−0.021	.013	3	view →
LUSC	All	III,IV	−0.130	.018	2	view →
BRCA	All	IV	−0.100	.046	2	view →
BLCA	Male	IV	−0.084	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TATDN2P3–KIRC

Open the KIRC breakdown →